Format

Send to

Choose Destination
Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Author information

1
The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: moverman@mdanderson.org.
2
St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland.
3
Allina Health System, Minneapolis, MN, USA.
4
Istituto Oncologico Veneto IOV-IRCSS, Padova, Italy.
5
USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
6
Duke University Medical Center, Durham, NC, USA.
7
Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Victoria, VIC, Australia.
8
Tasman Oncology Research Ltd, Southport, Queensland, QLD, Australia.
9
Bristol-Myers Squibb, Princeton, NJ, USA.
10
Bristol-Myers Squibb, Braine-L'Alleud, Belgium.
11
The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
12
Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris and Sorbonne Universités, UMPC Paris 06, Paris, France.

Erratum in

Abstract

BACKGROUND:

Metastatic DNA mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemotherapy and exhibits high levels of tumour neoantigens, tumour-infiltrating lymphocytes, and checkpoint regulators. All of these features are associated with the response to PD-1 blockade in other tumour types. Therefore, we aimed to study nivolumab, a PD-1 immune checkpoint inhibitor, in patients with dMMR/MSI-H metastatic colorectal cancer.

METHODS:

In this ongoing, multicentre, open-label, phase 2 trial, we enrolled adults (aged ≥18 years) with histologically confirmed recurrent or metastatic colorectal cancer locally assessed as dMMR/MSI-H from 31 sites (academic centres and hospitals) in eight countries (Australia, Belgium, Canada, France, Ireland, Italy, Spain, and the USA). Eligible patients had progressed on or after, or been intolerant of, at least one previous line of treatment, including a fluoropyrimidine and oxaliplatin or irinotecan. Patients were given 3 mg/kg nivolumab every 2 weeks until disease progression, death, unacceptable toxic effects, or withdrawal from study. The primary endpoint was investigator-assessed objective response as per Response Evaluation Criteria in Solid Tumors (version 1.1). All patients who received at least one dose of study drug were included in all analyses. This trial is registered with ClinicalTrials.gov, number NCT02060188.

FINDINGS:

Of the 74 patients who were enrolled between March 12, 2014, and March 16, 2016, 40 (54%) had received three or more previous treatments. At a median follow-up of 12·0 months (IQR 8·6-18·0), 23 (31·1%, 95% CI 20·8-42·9) of 74 patients achieved an investigator-assessed objective response and 51 (69%, 57-79) patients had disease control for 12 weeks or longer. Median duration of response was not yet reached; all responders were alive, and eight had responses lasting 12 months or longer (Kaplan-Meier 12-month estimate 86%, 95% CI 62-95). The most common grade 3 or 4 drug-related adverse events were increased concentrations of lipase (six [8%]) and amylase (two [3%]). 23 (31%) patients died during the study; none of these deaths were deemed to be treatment related by the investigator.

INTERPRETATION:

Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.

FUNDING:

Bristol-Myers Squibb.

PMID:
28734759
PMCID:
PMC6207072
DOI:
10.1016/S1470-2045(17)30422-9
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center